Gene · 1022
Papers3,996
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,996
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network. | Sci Adv | 2025 | 40020069 | PubTator, text mining | PubMed |
| Beneficial effects of Lactiplantibacillus plantarum BGPKM22 manifest only in interaction with healthy, but not with diseased human bronchial epithelial cells. | Benef Microbes | 2025 | 39970930 | PubTator, text mining | PubMed |
| Self-supervision advances morphological profiling by unlocking powerful image representations. | Sci Rep | 2025 | 39929956 | PubTator, text mining | PubMed |
| De-JAKing resistance with CDK7 inhibitors in post-MPN sAML. | Blood | 2025 | 39913336 | PubTator, text mining | PubMed |
| Targeting RNA modification and mitochondrial metabolism cross talk in leukemic stem cells with CDK7 inhibitor TGN-1062. | Blood Adv | 2025 | 39908477 | PubTator, text mining | PubMed |
| Erratum for Kar et al., "Cimicifugin, a broad-spectrum inhibitor of Theileria annulata and Plasmodium falciparum CDK7". | Antimicrob Agents Chemother | 2025 | 39853122 | PubTator, text mining | PubMed |
| Classical cell cycle kinase limits tubulin polyglutamylation and cilium stability. | J Cell Biol | 2025 | 39812708 | PubTator, text mining | PubMed |
| Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells. | Cancer Lett | 2025 | 39798832 | PubTator, text mining | PubMed |
| Identification of mitoxantrone as a potent inhibitor of CDK7/Cyclin H via structure-based virtual screening and In-Vitro validation by ADP-Glo kinase assay. | Bioorg Chem | 2025 | 39787913 | PubTator, text mining | PubMed |
| Oncogenic RARγ isoforms promote head and neck cancer proliferation through vinexin-β-mediated cell cycle acceleration and autocrine activation of EGFR signal. | Int J Biol Sci | 2025 | 39744424 | PubTator, text mining | PubMed |
| CDK2-based CDK7 mimic as a tool for structural analysis: Biochemical validation and crystal structure with SY5609. | Int J Biol Macromol | 2025 | 39733900 | PubTator, text mining | PubMed |
| Blocking CDK7 attenuates inflammatory arthritis. | Nat Rev Rheumatol | 2025 | 39706909 | PubTator, text mining | PubMed |
| Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer. | Anticancer Drugs | 2025 | 39671264 | PubTator, text mining | PubMed |
| Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple-Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1-Regulated Cholesterol Metabolism. | Adv Sci (Weinh) | 2025 | 39656925 | PubTator, text mining | PubMed |
| The role of super-enhancers in head and neck cancer and its potential therapeutic targets. | J Stomatol Oral Maxillofac Surg | 2025 | 39631527 | PubTator, text mining | PubMed |
| Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis. | Mol Cancer Ther | 2025 | 39588561 | PubTator, text mining | PubMed |
| Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. | Blood | 2025 | 39561280 | PubTator, text mining | PubMed |
| Emerging roles of cyclin-dependent kinase 7 in health and diseases. | Trends Mol Med | 2025 | 39414519 | PubTator, text mining | PubMed |
| Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth. | Haematologica | 2025 | 39049606 | PubTator, text mining | PubMed |
| Keep calm and reboot - how cells restart transcription after DNA damage and DNA repair. | FEBS Lett | 2025 | 38991979 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1022/papers?page=8